Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation
暂无分享,去创建一个
D. Holtzman | D. Selkoe | J. Cirrito | Ting Yang | Omar Quintero-Monzon | Soyon Hong | B. Ostaszewski | D. R. Podlisny | William Cavanaugh
[1] F. Grodstein,et al. Relation Between Insulin, Insulin-related Factors, and Plasma Amyloid Beta Peptide Levels at Midlife in a Population-based Study , 2012, Alzheimer disease and associated disorders.
[2] Li-Huei Tsai,et al. Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis , 2010, The Journal of Neuroscience.
[3] J. Trojanowski,et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology , 2010, Annals of neurology.
[4] Seiji Nishino,et al. Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.
[5] D. Selkoe,et al. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life , 2009, Neurobiology of Disease.
[6] Yan Wang,et al. Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice , 2009, The Journal of Neuroscience.
[7] David L. Brody,et al. Amyloid-ss Dynamics Correlate with Neurological Status in the Injured Human Brain , 2009 .
[8] D. Galimberti,et al. Faculty Opinions recommendation of Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. , 2009 .
[9] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[10] Kristina D. Micheva,et al. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques , 2009, Proceedings of the National Academy of Sciences.
[11] J. Schwalb,et al. Normal pressure hydrocephalus: Diagnosis and treatment , 2008, Current neurology and neuroscience reports.
[12] David L. Brody,et al. Amyloid-β Dynamics Correlate with Neurological Status in the Injured Human Brain , 2008, Science.
[13] Shaomin Li,et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.
[14] Guojun Bu,et al. Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo , 2008, Neuron.
[15] D. Selkoe,et al. Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.
[16] Ilka Wittig,et al. Advantages and limitations of clear‐native PAGE , 2005, Proteomics.
[17] Marvin Bergsneider,et al. Diagnosing Idiopathic Normal-pressure Hydrocephalus , 2005, Neurosurgery.
[18] P. T. Nguyen,et al. Dendritic Spine Abnormalities in Amyloid Precursor Protein Transgenic Mice Demonstrated by Gene Transfer and Intravital Multiphoton Microscopy , 2005, The Journal of Neuroscience.
[19] S. Grimwood,et al. Determination of guinea-pig cortical γ-secretase activity ex vivo following the systemic administration of a γ-secretase inhibitor , 2005, Neuropharmacology.
[20] Dominic M. Walsh,et al. Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.
[21] U. Ungerstedt,et al. Microdialysis in neurointensive care. , 2004, Current pharmaceutical design.
[22] D. Holtzman,et al. In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.
[23] C. Lemere,et al. Intranasal immunotherapy for the treatment of Alzheimer’s disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants , 2002, Neurobiology of Aging.
[24] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[25] Mikio Shoji,et al. Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.
[26] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[27] A. Kluger,et al. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response , 2000, Journal of neurology, neurosurgery, and psychiatry.
[28] C. Masters,et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.
[29] L. Lue,et al. Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .
[30] R. Nicoll,et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[31] W. Halliday,et al. Neuropathological Changes in Chronic Adult Hydrocephalus: Cortical Biopsies and Autopsy Findings , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[32] R. Motter,et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .
[33] M. Staufenbiel,et al. Electrophoretic Separation of βA4 Peptides (1–40) and (1–42) , 1996 .
[34] R. Wolfert,et al. Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .
[35] S. Younkin,et al. Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain , 1995, The Journal of Biological Chemistry.
[36] T. Iwatsubo,et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.
[37] D. Selkoe,et al. Isolation of Low‐Molecular‐Weight Proteins from Amyloid Plaque Fibers in Alzheimer's Disease , 1986, Journal of neurochemistry.
[38] A. Hamberger,et al. Mass transfer in brain dialysis devices—a new method for the estimation of extracellular amino acids concentration , 1985, Journal of Neuroscience Methods.
[39] C. Masters,et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[40] S. Grimwood,et al. Determination of guinea-pig cortical gamma-secretase activity ex vivo following the systemic administration of a gamma-secretase inhibitor. , 2005, Neuropharmacology.
[41] P. Hare. Advance Online Publication , 2002, Nature Medicine.
[42] S. Younkin,et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[43] M. Ishikawa,et al. [Normal pressure hydrocephalus]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.
[44] G. Waldemar,et al. Shunting Effects in Patients with Idiopathic Normal Pressure Hydrocephalus; Correlation with Cerebral and Leptomeningeal Biopsy Findings , 1999, Acta Neurochirurgica.
[45] L. Lue,et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.
[46] M. Staufenbiel,et al. Electrophoretic separation of betaA4 peptides (1-40) and (1-42). , 1996, Analytical biochemistry.
[47] D. Galasko,et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. , 1995, Annals of neurology.
[48] T. Iwatsubo,et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.